Fig. 8

Combination of TKIs synergistically inhibited human ccRCC growth in vivo. a and b. The body weights and tumor volumes during the drug treatment. The ccRCC xenograft nude mice were treated with vehicle, crizotinib (Cri), lapatinib (Lap), or combination of them for 21 days. Tumors were excised and photographed at the end of treatments. c. The tumor weights at the end of treatment. D. Tumors from ccRCC xenograft nude mice. e. Western blotting analyses of P-Met, P-EGFR, P-Erk1/2 and P-Akt levels of the tumors. The numbers underneath the groups represent the serial number of mice. Tumor lysates were processed for Western blot analyses and probed with the indicated antibodies. f. The ratios of protein phosphorylation levels relative to GAPDH. P < 0.05 (*), P < 0.01 (**), and P < 0.001(***) vs. vehicle group. Drug combination group was compared with the crizotinib group or lapatinib group (P < 0.05, #). Data were represented as mean ± SEM